These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.

The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.

The French in vitro diagnostics company slightly lowered its full-year revenue guidance to adjust for a late respiratory infection season.

The next-generation sequencing-based test is designed to capture all clinically relevant cystic fibrosis mutations in a single assay.